Abvc Biopharma (ABVC) Total Debt (2014 - 2026)
Abvc Biopharma's (ABVC) quarterly Total Debt came in at $88737.0 in Q1 2026, down 88.93% YoY from $801407.0 in Q1 2025, and down 88.25% on a QoQ basis from $755512.0 in Q4 2025.
Abvc Biopharma (ABVC) Total Debt (2014 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 12 years of Total Debt data on file, last reported at $88737.0 in Q1 2026.
- Quarterly Total Debt fell 88.93% year-over-year to $88737.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88737.0 (down 88.93% YoY) and the FY2025 annual result came in at $755512.0, down 10.09% from the prior year.
- Total Debt retreated to $88737.0 in Q1 2026, from $755512.0 in the prior quarter.
- In the past five years, Total Debt ranged from a high of $1.9 million in Q4 2022 to a low of $88737.0 in Q1 2026.
- A 5-year average of $818419.8 and a median of $847000.0 in 2024 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2023 — Total Debt soared 88.68% — and 2026, when it tumbled 88.93%.
- Tracing ABVC's Total Debt over 5 years: stood at $1.9 million in 2022, then slumped by 52.51% to $899250.0 in 2023, then slipped by 6.56% to $840252.0 in 2024, then fell by 10.09% to $755512.0 in 2025, then tumbled by 88.25% to $88737.0 in 2026.
- The last three Total Debt figures came in at $88737.0 (Q1 2026), $755512.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.34 Bn |
| 10 | Abvc Biopharma | 23.97 Mn | 23.97 Mn | - | 59,462.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59,462.00 |
| Mar 31, 2026 | 88,737.00 |
| Dec 31, 2025 | 755,512.00 |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 871,951.00 |
| Mar 31, 2025 | 801,407.00 |
| Dec 31, 2024 | 840,252.00 |
| Sep 30, 2024 | 896,250.00 |
| Jun 30, 2024 | 847,000.00 |
| Mar 31, 2024 | 860,750.00 |
| Dec 31, 2023 | 899,250.00 |
| Sep 30, 2023 | 852,500.00 |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 451,826.00 |
| Jun 30, 2022 | 461,612.00 |
| Mar 31, 2022 | 446,397.00 |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 402,436.00 |
| Jun 30, 2021 | 1.87 Mn |
| Mar 31, 2021 | 1.85 Mn |